StockData
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc. (SPRO) income statement

SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/3048% below fair value
$0.83−0.05 (-5.46%)

Close on Nov 19, 2026Market cap $48.12MP/E 20.7Yield –

See a number that looks wrong?